TNFA Overview

Company Name and Ticker Change: Q/C Technologies, Inc. has officially changed its name from TNF Pharmaceuticals, Inc. and will now trade under the ticker symbol "QCLS" on Nasdaq, marking a strategic shift towards quantum-class computing.

Focus on Quantum-Class Computing: The company has secured exclusive global rights to LightSolver's light-speed laser processing unit, aiming to leverage this technology for high-performance computing in cryptocurrency applications, positioning itself as a leader in this emerging field.

Corporate Name Change: TNF Pharmaceuticals has changed its corporate name to Q/C Technologies.

New Ticker Symbol: The company's stock will trade under the new ticker symbol "QCLS" on Nasdaq starting September 25, 2025.

Strategic Shift: The name change reflects the company's strategic pivot towards quantum-class computing.

Press Release Mention: The announcement was made through a press release, indicating a formal communication of the changes.

Company Name and Ticker Change: TNF Pharmaceuticals, Inc. has rebranded to Q/C Technologies, Inc. and will trade under the new ticker symbol "QCLS" on the Nasdaq Capital Market starting September 25, 2025.

Focus on Quantum-Class Computing: The company is pivoting towards quantum-class computing with exclusive rights to LightSolver's laser processing technology, which aims to enhance energy efficiency and performance in blockchain applications, particularly in cryptocurrency.

Presentation Announcement: TNF Pharmaceuticals, Inc. will present at the H.C. Wainwright & Co. 27th Annual Global Investment Conference on September 10, 2025, at 8:00 a.m. ET, located at the Lotte New York Palace Hotel in New York City.

Investor Meetings: In addition to the presentation, TNF management will engage in one-on-one investor meetings on-site and virtual meetings throughout the conference, with scheduling available on the conference website.

Forward-Looking Statements: The press release includes cautionary statements regarding forward-looking statements, highlighting risks and uncertainties that could affect the company's future performance and results.

Contact Information: For further inquiries, investors can contact TNF Pharmaceuticals at 800-507-9010 or visit their website for more information.

Financing Details: TNF Pharmaceuticals closed a $7 million private placement of convertible preferred stock, priced at a 44% premium to the market, involving significant participation from its largest strategic investor and existing stockholders.

Use of Funds: The capital raised is intended to support key development milestones for TNF's innovative technology, which is a light-based computing accelerator for blockchain, as well as ongoing development of pharmaceutical assets like isomyosamine and Supera-CBD.

PharmaCyte Biotech's Investment: PharmaCyte Biotech has increased its investment in TNF Pharmaceuticals by $3 million to support TNF's acquisition of a license from LightSolver, a company recognized for its innovative computing technology that significantly reduces energy consumption and enhances computational speed.

Future Prospects and Strategy: TNF Pharmaceuticals plans to rebrand and focus on applying LightSolver's technology to cryptocurrency mining and blockchain, while PharmaCyte remains financially strong with over $55 million in assets and is exploring further investment opportunities.